CClinicalTrials.gg
CompletedNCT02739789Updated Jul 8, 2020Results posted

Activating and Identifying Neural Responses to Social Rejection: a Combined tDCS and fMRI Study

An interventional study of tDCS and Sham tDCS in Healthy, sponsored by Stony Brook University. Completed at 1 site in United States. Open to participants aged 18 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-08.

Sponsored by Stony Brook University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years to 25 Years
Sex
All
01

Study summary

This research study identifies neural pathways regulating negative moods during rejection by combining transcranial direct current stimulation (tDCS) and fMRI in a sample of healthy controls.

Read the detailed description

Aim 1: To test the behavioral effects of tDCS during social rejection. The first step will be to obtain behavioral effects of transcranial direct current stimulation (tDCS) during social rejection without functional magnetic resonance imaging (fMRI). Whereas previous studies used "Cyberball" (a computerized ball-tossing game that simulates social exclusion), we will use the Social Feedback Task. This task was created by Dr. Hsu to be more ethologically-relevant, has been shown to sustain negative moods during rejection and activates the right ventral lateral prefrontal cortex (rVLPFC) (preliminary fMRI data from 50 healthy controls in Dr. Hsu's previous study). Anodal tDCS will be applied over the right or left VLPFC to measure changes in mood during rejection and neutral conditions. Depending on results, alternate regions in separate subjects may also be stimulated: dorsolateral prefrontal cortex, insula, anterior cingulate cortex, pre-supplementary, and supplementary motor area [all regions may be right or left hemisphere]. All of these regions have been shown to be involved in emotion regulation. Questionnaires will be given before, during, and after the task to assess cognitive and emotional states.

Aim 2: To identify neural pathways regulating negative moods during social rejection, using tDCS for activation and fMRI for assessment. Using a cross-over, sham-controlled design similar to previous tDCS+fMRI studies, we will measure the effects of anodal tDCS over the right or left VLPFC on neural activity and negative mood during rejection and neutral conditions. Alternate regions in separate subjects may also be stimulated including the dorsolateral prefrontal cortex, insula, anterior cingulate cortex, pre-supplementary, and supplementary motor area [all regions may be right or left hemisphere]. All of these regions have been shown to be involved in emotion regulation.

02

Conditions studied

  • Healthy

Keywords

  • tDCS rejection affect mood fMRI
03

In context

Lead sponsor

Stony Brook University is the lead sponsor of 191 studies on the registry; 36 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 10 (45%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Healthy males or females between 18 and 25 years old
  2. No diagnosis on Axis I by Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders IV. No current, or within the past 5 years.
  3. Not currently in a romantic relationship
  4. Ability to understand and follow instructions and oriented to name, time, and place.
  5. No additional neurologic or psychiatric disorders
  6. No current use of psychotropic drugs or during past 3 months (except marijuana and alcohol)
  7. No current use of marijuana or during past 3 weeks
  8. Not currently abusing alcohol
  9. No history of alcohol or drug dependence within past 5 years
  10. A negative urine pregnancy and toxicology screen. Verbal affirmation will be obtained (i.e., "not pregnant" and "not currently using psychotropic drugs or during the past 3 months") during the Screening Visit (Day 1). Urine screen will be obtained on Days 2 and 3. If subject reports that there is a "possibility that she is pregnant" on Day 1 (Screening Visit) a urine pregnancy screen will be performed on that day.
  11. (Women): If stopped or started oral contraceptives recently, at least 60 days on/off oral contraceptives.

Exclusion criteria

Exclusion Criteria:

  1. Left-handed or ambidextrous
  2. Metallic dental implants
  3. Metallic objects in the brain/skull
  4. Medical device implants
  5. Implanted electronic devices
  6. History of seizures
  7. History of strokes
  8. Unexplained loss of consciousness
  9. Frequent or severe headaches or neck pain
  10. Clinically significant, uncontrolled liver, kidney, cardiac, or pulmonary disease
  11. Terminal medical diagnosis consistent with survival \< 1 year
  12. Pregnancy; childbirth or miscarriage within 6 months, breastfeeding within 6 months of recruitment
  13. Serious mental impairment. Mini mental state exam of \< 23/30
  14. Chronic skin disease
  15. Previous experience with transcranial direct current stimulation (tDCS)
  16. Regular tobacco use or tobacco use within past month
  17. If using hormonal birth control, taking progestin-only pills (e.g., Cerazette, Ovrette), or Intrauterine devices (Mirena, Skyla), since progestin-only birth controls are more likely to cause mood swings.

Addition Exclusion Criteria for participating in fMRI:

  1. Metal anywhere in the body
  2. Weight over 250 pounds, or girth size incompatible for scanner bore.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
19 participants (actual)

Study arms

  • Sham comparator
    Sham tDCS

    tDCS stimulation will be administered over the brain area of interest, but will be shorter in duration than the "active" treatment

    Device: Sham tDCS

  • Active comparator
    Active tDCS

    tDCS stimulation will be administered over the brain area of interest

    Device: tDCS

Interventions

  • DevicetDCS

    tDCS

  • DeviceSham tDCS

    Sham tDCS

06

What researchers measure

Primary outcomes

  1. Blood Oxygen Level Dependent (BOLD) Signal Changes (in Arbitrary Units)

    Images from fMRI scans for each participant are preprocessed (e.g., realigned, normalized, smoothed). Changes in BOLD signal are modeled for rejection and acceptance vs neutral blocks, and contrast images are created. These contrast images are used to compare tDCS vs sham for each subject in a within-subjects analysis. BOLD responses are reported as arbitrary units (i.e., change from sham stimulation). Regions of interest include left and right ventrolateral prefrontal cortex (VLPFC), left and right nucleus accumbens (NAcc), left and right amygdala (Amyg), left and right anterior insula (AI), left and right dorsal anterior cingulate cortex (dACC).

    Time frame: 1-3 weeks

  2. Change in Positive and Negative Affect Scale (During fMRI)

    Change in emotion will be measured on the "Positive and Negative Affect Scale." During Rejection, Acceptance, and Neutral conditions, participants rate how much they feel "sad," "rejected," "happy," and "accepted" on a visual analog scale from "not at all" (minimum score of "0") to "extremely" (maximum score of "100"). Scores for "sad" were averaged with "rejected," and scores for "happy" were averaged with "accepted." The averaged scores during Neutral were subtracted from Rejection and Acceptance to derive the outcome measures. Higher outcome measure score means that the participant felt more of that particular emotion during a particular condition (minus neutral). Thus, a higher score for "happy and accepted" during the Acceptance-Neutral condition means a better outcome. Similarly, a lower score for "happy and accepted' during Rejection-Neutral condition means a worse outcome.

    Time frame: 1-3 weeks

  3. Change in the Single-item Self-Esteem Scale (During fMRI)

    Change in self-esteem will be measured on the "Single-item Self-Esteem Scale." During Rejection, Acceptance, and Neutral conditions, participants respond to the item "I have high self-esteem" on a visual analog scale from "not at all true of me" (minimum score of "0") to "very true of me" (maximum score of "100"). Scores during Neutral were subtracted from Rejection and Acceptance to derive the outcome measures. Higher outcome measure score means that the participant had more self-esteem, and thus a better outcome, during a particular condition (minus neutral).

    Time frame: 1-3 weeks

  4. Change in Desire for Social Interaction Scale (During fMRI)

    Change in Desire for Social Interaction will be measured on the "Desire for Social Interaction Scale." During Rejection, Acceptance, and Neutral conditions, participants respond to four items measuring desire for social interaction (e.g., "I would enjoy social interaction right now") on a visual analog scale from "very slightly or not at all" (minimum score of "0") to "extremely" (maximum score of "100"). Scores during Neutral were subtracted from Rejection and Acceptance to derive the outcome measures. Higher outcome measure score means that the participant had greater desire for social interaction, and thus a better outcome, during a particular condition (minus neutral).

    Time frame: 1-3 weeks

07

Results

Posted Jul 8, 2020

Participant flow

First fMRI Scan
Participant flow — First fMRI Scan
MilestoneSham tDCS First, Then Active tDCSActive tDCS First, Then Sham tDCS
Started910
Completed910
Not completed00
~1 Week Waiting Period
Participant flow — ~1 Week Waiting Period
MilestoneSham tDCS First, Then Active tDCSActive tDCS First, Then Sham tDCS
Started910
Completed97
Not completed03
Second fMRI Scan
Participant flow — Second fMRI Scan
MilestoneSham tDCS First, Then Active tDCSActive tDCS First, Then Sham tDCS
Started97
Completed97
Not completed00

Outcome measures

PrimaryBlood Oxygen Level Dependent (BOLD) Signal Changes (in Arbitrary Units)

Images from fMRI scans for each participant are preprocessed (e.g., realigned, normalized, smoothed). Changes in BOLD signal are modeled for rejection and acceptance vs neutral blocks, and contrast images are created. These contrast images are used to compare tDCS vs sham for each subject in a within-subjects analysis. BOLD responses are reported as arbitrary units (i.e., change from sham stimulation). Regions of interest include left and right ventrolateral prefrontal cortex (VLPFC), left and right nucleus accumbens (NAcc), left and right amygdala (Amyg), left and right anterior insula (AI), left and right dorsal anterior cingulate cortex (dACC).

Time frame:
1-3 weeks
Reported as:
Mean · Arbitrary units
Blood Oxygen Level Dependent (BOLD) Signal Changes (in Arbitrary Units)
Arbitrary unitsSham tDCSActive tDCS
left VLPFC (Rejection-Neutral).57 ± .77.66 ± .80
right VLPFC (Rejection-Neutral).25 ± .49.29 ± .38
left VLPFC (Acceptance-Neutral).67 ± .84.33 ± .77
right VLPFC (Acceptance-Neutral).40 ± 1.14.31 ± .72
left NAcc (R-N).01 ± .25.18 ± .42
right NAcc (R-N).05 ± .30.24 ± .53
left NAcc (A-N).09 ± .38.27 ± .38
right NAcc (A-N).17 ± .38.34 ± .58
left Amyg (R-N).2 ± .36.39 ± .45
right Amyg (R-N).19 ± .41.35 ± .52
left Amyg (A-N).12 ± .43.11 ± .23
right Amyg (A-N).07 ± .43.19 ± .38
left AI (R-N).32 ± .49.38 ± .53
right AI (R-N).28 ± .49.23 ± .61
left AI (A-N).36 ± .60.32 ± .44
right AI (A-N).21 ± .86.17 ± .41
left dACC (R-N).04 ± .60.25 ± .67
right dACC (R-N).13 ± .45.21 ± .72
left dACC (A-N).09 ± .6.42 ± .62
right dACC (A-N).06 ± .59.32 ± .67
PrimaryChange in Positive and Negative Affect Scale (During fMRI)

Change in emotion will be measured on the "Positive and Negative Affect Scale." During Rejection, Acceptance, and Neutral conditions, participants rate how much they feel "sad," "rejected," "happy," and "accepted" on a visual analog scale from "not at all" (minimum score of "0") to "extremely" (maximum score of "100"). Scores for "sad" were averaged with "rejected," and scores for "happy" were averaged with "accepted." The averaged scores during Neutral were subtracted from Rejection and Acceptance to derive the outcome measures. Higher outcome measure score means that the participant felt more of that particular emotion during a particular condition (minus neutral). Thus, a higher score for "happy and accepted" during the Acceptance-Neutral condition means a better outcome. Similarly, a lower score for "happy and accepted' during Rejection-Neutral condition means a worse outcome.

Time frame:
1-3 weeks
Reported as:
Mean · score on a scale
Change in Positive and Negative Affect Scale (During fMRI)
score on a scaleSham tDCSActive tDCS
Rejection-Neutral conditions (sad and rejected)14.06 ± 18.8212.81 ± 14.72
Acceptance-Neutral conditions (sad and rejected)6.00 ± 20.63-3.33 ± 13.84
Rejection-Neutral conditions (happy and accepted)-10.94 ± 22.89-5.31 ± 20.37
Acceptance-Neutral conditions (happy and accepted)0 ± 22.2012.00 ± 25.48
PrimaryChange in the Single-item Self-Esteem Scale (During fMRI)

Change in self-esteem will be measured on the "Single-item Self-Esteem Scale." During Rejection, Acceptance, and Neutral conditions, participants respond to the item "I have high self-esteem" on a visual analog scale from "not at all true of me" (minimum score of "0") to "very true of me" (maximum score of "100"). Scores during Neutral were subtracted from Rejection and Acceptance to derive the outcome measures. Higher outcome measure score means that the participant had more self-esteem, and thus a better outcome, during a particular condition (minus neutral).

Time frame:
1-3 weeks
Reported as:
Mean · score on a scale
Change in the Single-item Self-Esteem Scale (During fMRI)
score on a scaleSham tDCSActive tDCS
Rejection-Neutral conditions-5.33 ± 18.46-2.67 ± 21.54
Acceptance-Neutral conditions0.71 ± 12.698.57 ± 28.78
PrimaryChange in Desire for Social Interaction Scale (During fMRI)

Change in Desire for Social Interaction will be measured on the "Desire for Social Interaction Scale." During Rejection, Acceptance, and Neutral conditions, participants respond to four items measuring desire for social interaction (e.g., "I would enjoy social interaction right now") on a visual analog scale from "very slightly or not at all" (minimum score of "0") to "extremely" (maximum score of "100"). Scores during Neutral were subtracted from Rejection and Acceptance to derive the outcome measures. Higher outcome measure score means that the participant had greater desire for social interaction, and thus a better outcome, during a particular condition (minus neutral).

Time frame:
1-3 weeks
Reported as:
Mean · score on a scale
Change in Desire for Social Interaction Scale (During fMRI)
score on a scaleSham tDCSActive tDCS
Rejection-Neutral conditions-16.88 ± 35.72-13.75 ± 30.30
Acceptance-Neutral conditions-2.00 ± 14.241.33 ± 19.22

Adverse events

Collected over Adverse event data were collected over the duration of time over which each participant was assessed. This was an average of 30 days (standard deviation = 16 days, range = 14 - 74 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sham tDCS0/19 (0%)0/19 (0%)0/19 (0%)
Active tDCS0/19 (0%)0/19 (0%)0/19 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sham tDCSActive tDCSTotal
Mean21.89 ± 2.3721.71 ± 1.8021.81 ± 2.07
Sex: Female, Male
Sex: Female, Male(Participants)Sham tDCSActive tDCSTotal
Female448
Male538
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sham tDCSActive tDCSTotal
Race/Ethnicity — White or Caucasian538
Race/Ethnicity — Black or African American011
Race/Ethnicity — Hispanic or Latino000
Race/Ethnicity — Asian336
Race/Ethnicity — American Indian or Alaskan Native000
Race/Ethnicity — Other or mixed101
08

Study locations

1 site
  • Stony Brook University
    Stony Brook, New York 11794-8101, United States
09

References and documents

Study documents

  • Protocol, analysis plan and consent form · Apr 21, 2020

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02739789
Lead sponsor
Stony Brook University
Responsible party
David Hsu (Assistant Professor of Psychiatry, Stony Brook University) — Principal investigator
First posted
Apr 15, 2016
Start date
Feb 14, 2018
Primary completion
Oct 16, 2018
Completion
Oct 16, 2018
Results posted
Jul 8, 2020
Last update
Jul 8, 2020

Study contacts

David T Hsu, PhD
principal investigator · Stony Brook University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion